Regeneron Pharmaceuticals, Inc.
fianlimab
first-line metastatic melanoma
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for fianlimab (first-line metastatic melanoma) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 14h ago
“The Company remains on track to report results from the Phase 3 study of fianlimab in combination with cemiplimab versus pembrolizumab in first-line metastatic melanoma in the second quarter of 2026.”